JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB223602

PFI-3, bromodomain and SMARCA4 inhibitor

Be the first to review this product! Submit a review

|

(4 Publications)

MW 321.4 Da, Purity >98%. Potent and selective inhibitor of Polybromo (Kd = 48 nM) and SMARCA4 (Kd = 89 nM). Also inhibits SMARCA2. Displays high specificity for Family VIII bromodomains. PFI-3 displays selectivity against a range of other kinases. In a panel of 103 receptors and enzymes, activity was observed only against 4 GPCRs. At a concentration of 1 μM, PFI-3 accelerates FRAP recovery in cells.

View Alternative Names

ATP-dependent helicase SMARCA4, BAF 190, BAF180, BAF190A, BRG1 protein, BRG1-associated factor 180, BRG1-associated factor 190A, BRM/SWI2 related gene 1, Brahma protein like 1, CG11375, Global transcription activator homologous sequence, Homeotic gene regulator, MGC156155, MGC156156, MRD16, Mitotic growth and transcription activator, Nuclear protein GRB1, OTTHUMP00000202149, OTTHUMP00000202150, OTTHUMP00000202151, OTTHUMP00000202153, OTTHUMP00000202163, PB1_HUMAN, Pbrm1, Polybromo-1D, Protein BRG-1, Protein brahma homolog 1, Protein polybromo-1, RTPS2, SMARC A4, SMCA4_HUMAN, SNF2, SNF2 like 4, SNF2-beta, SNF2B, SNF2L4, SNF2LB, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4, SWI2, Sucrose nonfermenting like 4, Transcription activator BRG1, global transcription activator snf2l4, hPB1, hSNF2b, polybromo 1

1 Images
Chemical Structure - PFI-3, bromodomain and SMARCA4 inhibitor (AB223602)
  • Chemical Structure

Lab

Chemical Structure - PFI-3, bromodomain and SMARCA4 inhibitor (AB223602)

2D chemical structure image of ab223602, PFI-3, bromodomain and SMARCA4 inhibitor

Key facts

CAS number

1819363-80-8

Purity

>98%

Form

Solid

form

Molecular weight

321.4 Da

Molecular formula

C<sub>1</sub><sub>9</sub>H<sub>1</sub><sub>9</sub>N<sub>3</sub>O<sub>2</sub>

PubChem

78243717

Nature

Synthetic

Biochemical name

(E)-1-(2-hydroxyphenyl)-3-((1R,4R)-5-(pyridin-2-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)prop-2-en-1-one

Biological description

Potent and selective inhibitor of Polybromo (Kd = 48 nM) and SMARCA4 (Kd = 89 nM). Also inhibits SMARCA2. Displays high specificity for Family VIII bromodomains. PFI-3 displays selectivity against a range of other kinases. In a panel of 103 receptors and enzymes, activity was observed only against 4 GPCRs. At a concentration of 1 μM, PFI-3 accelerates FRAP recovery in cells.

Canonical smiles

C1C2CN(C1CN2C3=CC=CC=N3)C=CC(=O)C4=CC=CC=C4O

Isomeric smiles

C1[C@@H]2CN([C@H]1CN2C3=CC=CC=N3)/C=C/C(=O)C4=CC=CC=C4O

InChi

InChI=1S/C19H19N3O2/c23-17-6-2-1-5-16(17)18(24)8-10-21-12-15-11-14(21)13-22(15)19-7-3-4-9-20-19/h1-10,14-15,23H,11-13H2/b10-8+/t14-,15-/m1/s1

InChiKey

INAICWLVUAKEPB-QSTFCLMHSA-N

IUPAC Name

(E)-1-(2-hydroxyphenyl)-3-[(1R,4R)-5-pyridin-2-yl-2,5-diazabicyclo[2.2.1]heptan-2-yl]prop-2-en-1-one

Product details

This product is manufactured by BioVision, an Abcam company and was previously called 2895 PFI-3. 2895-25 is the same size as the 25 mg size of ab223602.

Protect from air.

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
Store in the dark

Product protocols

Publications (4)

Recent publications for all applications. Explore the full list and refine your search

Epigenomics 9:919-931 PubMed28521512

2017

The BRG1 ATPase of human SWI/SNF chromatin remodeling enzymes as a driver of cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Qiong Wu,Jane B Lian,Janet L Stein,Gary S Stein,Jeffrey A Nickerson,Anthony N Imbalzano

Journal of medicinal chemistry 59:4800-11 PubMed27115555

2016

Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit.

Applications

Unspecified application

Species

Unspecified reactive species

Brian S Gerstenberger,John D Trzupek,Cynthia Tallant,Oleg Fedorov,Panagis Filippakopoulos,Paul E Brennan,Vita Fedele,Sarah Martin,Sarah Picaud,Catherine Rogers,Mihir Parikh,Alexandria Taylor,Brian Samas,Alison O'Mahony,Ellen Berg,Gabriel Pallares,Adam D Torrey,Daniel K Treiber,Ivan J Samardjiev,Brian T Nasipak,Teresita Padilla-Benavides,Qiong Wu,Anthony N Imbalzano,Jeffrey A Nickerson,Mark E Bunnage,Susanne Müller,Stefan Knapp,Dafydd R Owen

Science advances 1:e1500723 PubMed26702435

2015

Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance.

Applications

Unspecified application

Species

Unspecified reactive species

Oleg Fedorov,Josefina Castex,Cynthia Tallant,Dafydd R Owen,Sarah Martin,Matteo Aldeghi,Octovia Monteiro,Panagis Filippakopoulos,Sarah Picaud,John D Trzupek,Brian S Gerstenberger,Chas Bountra,Dominica Willmann,Christopher Wells,Martin Philpott,Catherine Rogers,Philip C Biggin,Paul E Brennan,Mark E Bunnage,Roland Schüle,Thomas Günther,Stefan Knapp,Susanne Müller

Cancer research 75:3865-3878 PubMed26139243

2015

The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.

Applications

Unspecified application

Species

Unspecified reactive species

Bhavatarini Vangamudi,Thomas A Paul,Parantu K Shah,Maria Kost-Alimova,Lisa Nottebaum,Xi Shi,Yanai Zhan,Elisabetta Leo,Harshad S Mahadeshwar,Alexei Protopopov,Andrew Futreal,Trang N Tieu,Mike Peoples,Timothy P Heffernan,Joseph R Marszalek,Carlo Toniatti,Alessia Petrocchi,Dominique Verhelle,Dafydd R Owen,Giulio Draetta,Philip Jones,Wylie S Palmer,Shikhar Sharma,Jannik N Andersen
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com